Chronic transfusion therapy effectiveness as primary stroke prophylaxis in sickle cell disease patients

AUTOR(ES)

Franco, Juliana Moreira; Borges, Carla Caroline Lopes; Ansaloni, Marília Alves; Mauro, Renata Dudnick de Lima; Souza, Ylle Carolinne da Cruz; Braga, Josefina Aparecida Pellegrini

FONTE

Hematol., Transfus. Cell Ther.

DATA DE PUBLICAÇÃO

2020-03

RESUMO

Abstract Introduction About 10% of sickle cell anemia patients will have ischemic stroke. Adams showed stroke incidence reduction in children receiving monthly erythrocyte transfusions by reducing transcranial Doppler (TCD) velocities. Since then, chronic transfusion is recommended as primary stroke prophylaxis. This study aims to assess the effectiveness of chronic transfusions as stroke prophylaxis. Method Retrospective study, reviewing medical records from 15 sickle cell anemia patients undergoing chronic transfusion. Data collected were age, sex, adverse reactions, stroke, hemoglobin, reticulocytes, ferritin, HbS and TCD values (baseline, after 12 and 24 months of treatment). Results The mean age was 118.67 ± 41.40 months; six patients experienced allergic reactions. No stroke was recorded. One patient had alloimmunization. There was a decrease in the HbS rate and an increase in hemoglobin values in the first 12 months. Values were maintained after 24 months, but with no improvement of data. Before treatment, the mean HbS rate was 75.18%±11.69; after 12 months, 41.63 ± 14.99 and after 24 months, 43.78 ± 10.6. Thirteen patients initiated chelation after 12 months from the beginning of chronic transfusions and ferritin decline after 24 months. Pre-transfusional TCD velocities were 204.28 ± 9.41 cm/s (right) and 198.85 ± 33.37 cm/s (left). After a 12-month treatment, these values were 158.5 ± 28.89 cm/s and 157.62 ± 34.43 cm/s, respectively, and this reduction was statistically significant (p = 0.002 right and p = 0.02 left). After 24 months, these values were 149.63 ± 26.95 cm/s (right) and 143.7 ± 32.27 cm/s (left). Conclusion Significant reduction of TCD velocity occurred after treatment with chronic transfusion in sickle cell anemia patients, leading to a normal or conditional test and reducing stroke risk in all but one patient.

Documentos Relacionados

• Neuromotor and functional outcomes in patients with sickle cell disease and stroke
• Pain measurement as part of primary healthcare of adult patients with sickle cell disease
• Effectiveness of biofeedback therapy in patients with chronic constipation
• Chronic synovitis with early cartilage destruction in sickle cell disease.
• Interleukin 8 as a vaso-occlusive marker in Brazilian patients with sickle cell disease